Trial Profile
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 12 Apr 2018 Status changed from recruiting to discontinued.
- 05 Mar 2018 Planned primary completion date changed from 30 Mar 2018 to 1 Dec 2018.
- 08 Aug 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2018.